MitoRx Therapeutics

Great to be at #bioequity24 supporting and representing MitoRx Therapeutics as we seek investors for our Series A raise. MitoRx Therapeutics is an Oxford based preclinical stage platform biotech developing mitochondrial-targeted small molecules that uniquely restore sulfide-signaling, a conserved system required for adaptive metabolism, recently achieving preclinical platform validation. We have generated positive results in 3 preclinical programs in neuromuscular, obesity and lung inflammatory disease. In a severe fibrotic rodent model of Duchenne MD muscle degeneration is halted and impaired weight gain is reversed, a unique metabolic rescue among muscular dystrophy efforts. In a rodent obesity model, we observed highly significant reduction in weight gain, inflammation and liver injury. In a COPD model with our compounds reduce fibrosis, blunt inflammasome activation and preserve function. MitoRx Therapeutics have raised £5m since 2022, built a team that has taken 5 drugs to market, and filed on five compositions of matter patents. Our approach in highly innovative: first in class, first in mechanism and first in target. We are seeking research collaboration and option deals with pharma and investors who want to back us to the clinic.

Excited to be sharing news of positive results in obesity, muscular dystrophy and lung inflammatory disease at #BioEquity represented here by Jon Rees and Rick Cousins. #mitochondrial #platform

Excellent meetings today at the #BioTrinity partnerning conference representing MitoRx Therapeutics as seek investors for our Series A and pharma partners for collaboration.

PUBLICATION ALERT! Congratulations to Prof Matt Whiteman (CSO at MitoRx), Dr Luke Slade and international colleagues on the publication of this excellent Review illustrating the evidence supporting development of mitochondriotropic H2S donors for therapeutic use in treating primary mitochondrial diseases. MitoRx Therapeutics is the sole worldwide biotech developing derisked and effective mitochondriotropic H2S donors. https://lnkd.in/eQi3DGm7

Our brilliant Scientific Advisory Board now has four new great minds appointed to it. The international experts joining our SAB are Caroline Le Guiner PhD, Milos Filipovic PhD, Philip Hansbro PhD, and Professor Annemieke Aartsma-Rus PhD. They bring a wealth of knowledge and experience in gene therapy, chemical biology, Duchenne Muscular Dystrophy, and respiratory #research. It’s amazing what great minds can achieve when they work together. Our first-in-class mitochondriotropic #therapeutic pipeline is aimed at restoring the function of sulfide-signaling, whose restoration can arrest progression in degenerative conditions like #DMD and #dementia, as well as lung inflammatory disease. Read the release here: https://lnkd.in/dGnPRjvG #Biotech #Mitochondria #Pharma

We’re delighted to have started March in Orlando, Florida, sharing some of our latest pre-clinical #research on #DMD in a poster at the MDA Clinical & Scientific Conference. This outstanding event has over 100 renowned expert presenters in dozens of sessions on the latest research advancements and #clinical achievements in #neuromuscular disease. See poster T426 here: https://lnkd.in/eqFJ3aCf Thanks to our collaborators on this translational research, including Australia’s Centenary Institute and England’s Royal Holloway, University of London. Our first-in-class mitochondriotropic #therapeutic pipeline is aimed at restoring the function of sulfide-signaling, whose restoration can arrest progression in degenerative conditions like #DMD and #dementia, as well as lung inflammatory disease. 🔬 Find our more here: https://lnkd.in/gjYVxVF6 Muscular Dystrophy Association #Biotech #Networking #Mitochondria #Therapeutics #Pharma #MDA #MDAconference

Today is Rare Disease Day, and we are shining a light on the importance of research, support, and addressing the challenges faced for some of the 300 million people who suffer from rare diseases. Our first-in-class mitochondriotropic treatments are aimed at restoring the function of sulfide-signaling, whose restoration can arrest the progression of rare conditions like #Duchenne muscular dystrophy (#DMD) and #dementia, as well as lung inflammatory disease. By pioneering these innovative #therapeutics we are striving to make a tangible difference in rare diseases and their profound impact on individuals and families worldwide. 🔗 www.rarediseaseday.org #RareDiseaseDay #Biotech #Mitochondria #Pharma

Our CEO & co-founder Dr Jon Rees is presenting in-person and digitally at BIO-Europe Spring in Barcelona. 📅 March 20 | 10:20 – 10:30 | Exhibit Hall Stage Jon will offer insights into our first-in-class mitochondriotropic therapeutic pipeline aimed at restoring the function of sulfide-signaling, whose restoration can arrest progression in degenerative conditions like #Duchenne muscular dystrophy and #dementia, as well as lung inflammatory disease. 🤝 #Partnering is OPEN, let’s schedule a meeting: https://lnkd.in/e2EQTn8j 🔬 Discover our mission to arrest the progression of degenerative diseases driven by mitochondrial dysfunction: https://lnkd.in/gjYVxVF6 #Biotech #Networking #Mitochondria #Therapeutics #Investment #Pharma #BIOEuropeSpring

Muscular Dystrophy Association is proud to announce our #RareDiseaseDay campaign, shedding light on innovations in research, care and advocacy to resolve the challenges faced by people living with neuromuscular disease. Follow along on our social channels as we share educational content all month, culminating on Rare Disease Day, February 29, to raise awareness about rare diseases and their impact on the people living with them. Learn more and join the campaign, supporting people with neuromuscular disorders and contributing to vital research and care initiatives at the link below. "For over 70 years, MDA has relentlessly pushed the boundaries of research in the rare neuromuscular disease space. Since leading the Genetic Task Force that discovered the Duchenne muscular dystrophy gene, MDA has been instrumental in paving the way for targeted treatment innovations. The creation of the NeuroMuscular ObserVational Research (MOVR) Data Hub marks another leap forward, revolutionizing our understanding of NMDs, enhancing patient outcomes, and propelling the development of groundbreaking treatments. MDA’s nationwide network of Care Centers ensures that people living with neuromuscular disease receive specialized, advanced care from medical professionals who are experts in the treatment of rare diseases. These are more than initiatives; they are real-world solutions impacting lives every day,” said Donald S. Wood, PhD, President and CEO, MDA.

Publication Alert! New publication in Cells this week suggests good evidence for hydrogen sulfide replenishment as a disease-modifying therapeutic strategy for Duchenne Muscular Dystrophy Cardiomyopathy, as spotted by our Head of IP Norman Law: